Angiotensin II receptor antagonists role in arterial hypertension

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S93-S99

  Hernandez Hernandez R ^a   Sosa Canache, B ^a   Velasco, M ^b   Armas Hernandez M J ^a   Armas Padilla, M C ^a   Cammarata, R ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Angiotensin II receptor antagonist; At1 receptor; At2 receptor; Losartan

Indexed keywords

2,7 DIETHYL 5 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5H PYRAZOLO[1,5 B][1,2,4]TRIAZOLE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CATECHOLAMINE; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FELODIPINE; FORASARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; LRB 081; SODIUM; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN; VASOPRESSIN; ZOLASARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CATECHOLAMINE RELEASE; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MARKETING; DRUG METABOLISM; DRUG TOLERABILITY; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART OUTPUT; HEART RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MONOTHERAPY; SMOOTH MUSCLE RELAXATION; SODIUM EXCRETION; UPPER RESPIRATORY TRACT INFECTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASOPRESSIN RELEASE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0036224563     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001352     Document Type: Article

References (58)

1. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardio-myocyte hypertrophy. Hypertension 1996; 28: 635-640.
2. Ford WR, Clanachan AS, Jugdutt BL. Opposite effects of angiotensin AT1 and AT2 receptor antagonist on recovery of mechanical function after ischemia-reper-fusion in isolated working rat heart. Circulation 1996; 94: 3087-3089.
3. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research. J Hyper-tens 1994; 12: S1-S5.
4. Streeten DH, Anderson GH Jr, Dalakos TH. Angiotensin II blockade: its clinical significance. Am J Med 1976; 60: 817-824.
5. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. Prog Cardiovasc Dis 1974; 17: 87-98.
6. Furukawa Y, Kishimoto S, Hishikawa K. Tadeka Chemical Industries Ltd. Hypotension imidazole-5 acetic acid derivatives. US Patent 4 355040, 20 July 1982.
7. Wexeler RR et al. Rationale for the chemical development of angiotensin II receptor antagonist. Am J Hyper-tens 1992; 5: 209S-220S.
8. Chuiu AT et al. Non peptide angiotensin II receptor antagonists, VIII: characterization of functional antagonism displayed by Dup-753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
9. Gansevoor RT et al. Effects of the angiotensin II antagonists losartan in hypertensive patients with renal disease. J Hypertens 1994; 12: S37-S42.
10. de Gasparro M, Bottari S, Levens NR. Characteristics of angiotensin II receptor and their role in cell and organ physiology. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology; Diagnosis and Management. Second edition. Raven Press Thd: New York, 1995, pp 1695-1720.
11. Israelli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitors therapy: a review of the literature and pathophysiology. Ann Inter Med 1992; 117: 234-242.
12. Timmermans PBMW et al. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 221S-234S.
13. Garcha RS, Sever PS, Hugles AD. Action of AT1-recep-tor antagonist on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol 1999; 127: 1876-1882.
14. Morsing P et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-1413.
15. Vanderheyden PML et al. Distinction between surmountable and insurmountable selective AT1-receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1-receptors. Br J Pharmacol 1999; 126: 1057-1065.
16. Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
17. Corriu C, Bernard S, Schott C, Stoclet JC. Effects of los-artan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995; 26: 688-692.
18. II Noda M et al. Inhibition of rabbit aortic angiotensin (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993; 46: 311-318.
19. Ohlstein E, Brooks D, Feuerstein G, Ruffolo Jr R. Inhi-bition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55: 244-251.
20. Hedner T. Management of hypertension: the advent of new angiotensin II receptor antagonist. J Hypertens 1999; 17 (Suppl 2): S21-S25.
21. Hein L et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-747.
22. Ichiki T et al. Effects on blood pressure and exploratory behaviour of mice lack angiotensin II type-2 receptor. Nature 1995; 377: 748-750.
23. Tsutsumi Y et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
24. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2000; 11: 1-6.
25. Hollenberg NK, Sever PS. The past, present and future of hypertension management: a potential role for AT1-receptor antagonists. JRAA 2000; 1: 5-10.
26. Sasamura H et al. Cloning, characterization and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Comun 1992; 351: 253-259.
27. de Gasparo M et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25: 924-927.
28. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1824.
29. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13: 62S-67S.
30. Wong PC et al. Non-peptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension 1990; 15: 823-834.
31. Markahm A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drug 1997; 54: 299-311.
32. Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens Suppl 1997; 15: S15-S20.
33. Criscione L et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Res 1995; 13: 230-250.
34. Weber MA. Comparison of type I angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension. J Hyper-tens 1997; 15: S32-S36.
35. Chan JCN et al. A randomised, double blind, parallel study of the antihypertensive efficacy and safety of los-artan potassium compared to felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765-771.
36. Mallion JM Goldberg AI. Global efficacy and toler-ability of losartan, and angiotensin II subtype 1-receptor antagonist, in treatment of hypertension. Blood Press Suppl 1996; 2: 82-86.
37. Soffer BA et al. Effects of losartan on a blackground of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
38. Gavras I, Gavras H. Effects of eprosartan versus enal-april in hypertensive patients on the renin angioten-sin-aldosterone system and safety parameters; results from a 26 week, double-blind, multicenter study. Curr Med Res Opin 1999; 15: 15-24.
39. Zanchetti A. Candesartan cilexitil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S57-S59.
40. Pouleur HG. Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertens 1997; 10 (Suppl): 318S-324S.
41. Ponticelli C, on behalf of the Eprosartan Study Group. Comparison of the efficacy of eprosartan and enalapril in patients with severe hypertension. Am J Hypertens 1997; 10: 128A (Abstract).
42. Mallion JM et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997; 2: 179-184.
43. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-335.
44. Oparil, S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13: 18S-24S.
45. Brunner H, Gavras H, Laragh JH, Keenan R. Angioten-sin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; II: 1045-1048.
46. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl 1): S73-S86.
47. Belt GG et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S45-S47.
48. Gradman AH et al. Assessment of once-daily eprosar-tan, an angiotensin II antagonist, in patients with systemic hypertension, Eprosartan Study Group. Clin Ther 1999; 21: 442-453.
49. Burnier M, Brunner HR. Angiotensin II receptor antagonists in hypertension. Kidney Intern 1998; 54 (Suppl 68): S107-S111.
50. Ruddy MC, Kostis JB. Angiotensin II receptor antagonist. In: Oparil S, Weber M (eds). Hypertension WB Saunders: Philadelphia, 1999.
51. Chap Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
52. Cruickshank JM et al. Reversivility of left ventricular hypertrophy by differing types of antyhipertensive therapy. J Hum Hypertens 1992; 6: 85-90.
53. Mizuno K et al. Effects of losartan, non-peptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992; 51: 367-374.
54. Bunkerburg B et al. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992; 20: 746-754.
55. Thurmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
56. Golbert AI, Dunlay MC, Sweet CS. Safety and toler-ability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochrothiazide, atenolol, felodipine AR and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
57. Chan P et al. Double-blind comparison of losartan, lisi-nopril and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37: 253-257.
58. Stettin G et al. One-year persistency and compliance with 5 major classes of antihypertensive therapy (abstract). Clin Pharmacol Ther 1998; 63: 197.